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Oral vitamin B12 and high-dose folic acid in hemodialysis pa- chronic morbidity [1, 2]. This high prevalence of ASCVD
tients with hyper-homocyst(e)inemia. is not fully explained by the increased rates of known
Background. Hyper-homocyst(e)inemia is an independent risk factors such as hypertension, hypercholesterolemia,risk factor for atherosclerotic vascular disease in patients with
and diabetes mellitus [3, 4]. Hyper-homocyst(e)inemiaend-stage renal disease (ESRD), although optimal treatment
is an independent risk factor for ASCVD in patients with-remains unknown. This randomized, double-blind, placebo-
controlled study was designed to measure the effect of high- out renal failure [5, 6]. More recently, it has been estab-
dose oral vitamin B12 and folic acid on predialysis total homo- lished as an independent risk factor for ASCVD in both
cyst(e)ine levels in patients with ESRD. retrospective [3, 7–11] and prospective studies [12, 13]
Methods. We studied 81 hemodialysis patients who had
for patients on dialysis. This is important since hyper-hyper-homocyst(e)inemia (.16 mmol/L) on varied doses of a
homocyst(e)inemia (.90th percentile control value) is themultivitamin containing 1 mg of folic acid/day. After screening
blood work, all patients were switched to daily multivitamin most prevalent risk factor for ASCVD in ESRD, oc-
therapy, including 1 mg of folic acid for four weeks. For all curring in 83 to 91% of patients [3, 11].
patients, vitamin B12, 1 mg/day, was added for an additional The physiological basis for hyper-homocyst(e)inemia
four weeks. Patients were then randomized to receive four
in renal failure is not clear [3, 14], but it is important toweeks of 0, 5, or 20 mg of folic acid in addition to the multivita-
consider since it forms the basis for therapy of hyper-min and vitamin B12 (all given daily).
Results. Screening homocyst(e)ine levels (mean 27.7 mmol/L) homocyst(e)inemia. Homocyst(e)ine is produced during
decreased by 19.2% after four weeks of treatment with a daily the breakdown of methionine, an essential amino acid,
multivitamin containing 1 mg of folic acid (P , 0.001). Homo- and can be metabolized by three separate pathways [15].cyst(e)ine levels were reduced further from 22.3 to 18.6 mmol/L
The remethylation pathway is the most important deter-(mean reduction 16.7%, 95% CI 11.8 to 21.6%, P , 0.001)
minant of the fasting homocyst(e)ine level and correlatesafter four weeks of therapy with vitamin B12 (1 mg/day). There
was no significant difference in mean reduction of homocys- best with atherosclerotic risk [16, 17]. Several mecha-
t(e)ine levels after therapy with high-dose folic acid compared nisms have been postulated to explain the reduction in
with placebo (P 5 0.35). activity of the remethylation pathway in renal failure,Conclusions. The optimal oral treatment of hyper-homocys-
including a subclinical deficiency of folic acid and vitamint(e)inemia in hemodialysis patients consists of 1 mg of folic
B12, two cofactors needed in the remethylation pathwayacid and 1 mg of oral vitamin B12 daily. Whether this treatment
will lower the risk of future atherosclerotic vascular events [3, 18, 19]. Another possible explanation for hyper-
remains to be investigated. homocyst(e)inemia is the important role of the kidney
in the normal metabolism of homocyst(e)ine [3, 19]. Two
recent studies have shown a marked increase in the half-
Atherosclerotic cardiovascular disease (ASCVD) is life of homocyst(e)ine in ESRD patients caused by a
the cause of death for 25 to 60% of patients with end- significant reduction in the clearance of homocyst(e)ine
stage renal disease (ESRD) and also is a major cause of by the kidney [3, 19]. This reduction in homocyst(e)ine
metabolism by the diseased kidneys may be exacerbated
by the very low levels of serine (an amino acid producedKey words: atherosclerotic vascular disease, end-stage renal disease,
serine, renal failure, remethylation pathway, homocyst(e)ine. in the kidney) commonly present in patients with ESRD,
since serine is needed as a methyl donor in the remethyla-Received for publication June 30, 2000
tion pathway [3, 7, 20, 21].and in revised form September 22, 2000
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quires higher doses of folic acid and vitamin B12 to to enrollment were switched to daily oral Diavitee for
four weeks. Baseline blood work was drawn for homo-achieve a considerable reduction in homocyst(e)ine lev-
els as compared with patients with normal renal function cyst(e)ine, red blood cell (RBC) folate, and vitamin B12
four weeks later (week 4). In phase 2, Diavitee was[22, 23]. No studies have compared monotherapy with
oral folic acid at the conventional dose used in ESRD continued, and oral vitamin B12 (Nature Madet; Phar-
mavite Corporation, Mississauga, Canada) at a dose ofpatients (that is, 1 mg folic acid per day) with higher
doses such as those used by previous studies (that is, 5 1 mg/day for four weeks was added in all patients. Blood
work was repeated (week 8). In phase 3, patients contin-to 15 mg per day) [22, 24, 25]. The role of isolated vitamin
B12 supplementation to reduce homocyst(e)ine levels has ued to receive Diavitee and vitamin B12 daily, and in
addition, they were randomized (using a computer-gen-not been studied in patients with ESRD who are not
vitamin B12 deficient. No large studies have examined the erated sequence) to receive either placebo, folic acid
(Apotex Inc., Toronto, Canada) 5 mg/day, or folic acidrole of serine deficiency in the hyper-homocyst(e)inemia
seen in ESRD patients and whether normalization of 20 mg/day for four weeks. Folic acid/placebo capsules
were dispensed in serially numbered containers and wereserine levels through supplementation could reduce
homocyst(e)ine levels. identical in size, shape, and color. Thus, patients, patient
caregivers, data collectors, and investigators were blindedTo assess these possibilities, a 14-week trial was con-
ducted consisting of three separate intervention phases to treatment allocation for folic acid therapy throughout
the trial. Blood work was repeated (week 12).to determine the most effective method of reducing
homocyst(e)ine levels in ESRD patients receiving hemo- In phase 4, the final 24 patients enrolled in the trial
(7 from “placebo,” 8 from “5 mg folic acid,” and 9 fromdialysis. Two phases were open label (vitamin B12 and
serine) and one was randomized, double blind, and pla- the “20 mg folic acid group”) continued Diavitee, vita-
min B12, and placebo/folic acid (all in the same doses),cebo controlled (folic acid).
and in addition, each received USP-grade l-serine at a
dose of 0.05 g/kg twice per day (total 0.1 g/kg/day) for
METHODS
a further two weeks. Following this, final blood work
Patients was drawn at week 14. After each phase of the trial,
compliance with therapy was assessed by pill counts.Hemodialysis patients who had a total homocyst(e)ine
level .16 mmol/L were enrolled from a single tertiary care
Research questionscenter in Calgary, Canada. Patients were excluded if they
had vitamin B12 (,130 pmol/L) or folate (,250 nmol/L) The primary research question was whether short-
term therapy with high-dose folic acid (5 or 20 mg) wasdeficiency, were currently receiving or had received
treatment with vitamin B12 injections or an average of more effective than placebo in lowering homocyst(e)ine
in vitamin B12-supplemented hemodialysis patients withgreater than 1 mg of folic acid per day in the past six
months, or were currently using antifolate or antiepilep- hyper-homocyst(e)inemia on maintenance multivitamin
therapy containing 1 mg of folic acid per day. Theretic medications (that is, phenytoin).
One hundred fifty-seven patients were screened for were three secondary research questions: (1) Does short-
term therapy with 1 mg of oral vitamin B12 daily lowerentry into the study. Twenty-six patients did not have
hyper-homocyst(e)inemia (.16 mmol/L). Forty-five were homocyst(e)ine in hemodialysis patients with hyper-
homocyst(e)inemia on maintenance multivitamin ther-unable or unwilling to participate, and hence, 86 patients
were enrolled in the study. At baseline, 92.6% of the apy? (2) Does supplementation with serine at 0.05 g/kg
twice per day lower homocyst(e)ine in hemodialysis pa-enrolled patients were taking supplemental folic acid and
B vitamins in the form of Diavitee (R&D Laboratories, tients with hyper-homocyst(e)inemia after supplementa-
tion with folic acid and vitamin B12? (3) What factors,Marina del Rey, CA, USA), which contains folic acid
1 mg, vitamin B12 6 mg, vitamin B6 3 mg, and small including baseline clinical characteristics, pre- or post-
RBC folate and vitamin B12 levels, and allocation toamounts of other vitamins. Of those who were taking
Diavitee, 56% used it daily and 44% used it three-times placebo/folic acid, predict a 50% lowering in screening
homocyst(e)ine level?per week postdialysis.
Protocol Laboratory evaluation
In all cases, blood work was drawn midweek and predi-The Conjoint Health and Research Ethics Board at
The University of Calgary approved the study protocol, alysis. Plasma homocyst(e)ine levels were measured us-
ing a fluorescence polarization immunoassay kit (IMX;which is depicted schematically in Figure 1. Patients were
screened for the presence of hyper-homocyst(e)inemia Abbott Laboratories, Mississauga, Ontario, Canada). The
standard deviation of the assay is 0.33 mmol/L, and thewith a midweek predialysis total homocyst(e)ine level
(week 0). During phase 1, eligible patients who agreed normal range for homocyst(e)ine in our laboratory is 4.9
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Fig. 1. Trial profile.
to 13.7 mmol/L in patients with normal renal function. cebo, 5 mg, and 20 mg folic acid groups were compared
using one-way analysis of variance for normally distrib-RBC folate and vitamin B12 levels were measured using
a radiodilution immunoassay kit (Ciba-Corning, Med- uted continuous variables and the Kruskal–Wallis test
for the screening homocyst(e)ine levels.icfield, MA, USA). In our laboratory, RBC folate and
vitamin B12 deficiency are defined by levels ,250 nmol/L One-way analysis of variance was used to compare
the mean difference in homocyst(e)ine levels before andand ,130 pmol/L, respectively. Plasma serine was deter-
mined using 5-sulfosalicylic acid-treated plasma samples after treatment with placebo, 5 mg or 20 mg of folic acid.
A paired, two-sided t test was used to compare the meanstored at 2708C. Samples were batch assayed using an
automated amino acid analyzer. Normal serine values difference in homocyst(e)ine levels before and after four
weeks of therapy with vitamin B12 and also before andfor adults with normal renal function in our laboratory
are 0.03 to 0.18 mmol/L. after two weeks of therapy with serine.
Multiple logistic regression was used to determine the
Statistical analysis factors predictive of a 50% lowering in screening homo-
cyst(e)ine level. The variables that were considered in-All analyses were performed according to the inten-
tion to treat principle and included all enrolled patients cluded age, number of years on dialysis, diabetes, screen-
ing homocyst(e)ine level, baseline and post-treatmentwho had at least two blood samples collected. Baseline
variables were described using the mean (for variables red blood cell (RBC) folate and vitamin B12 levels, and
treatment allocation. Backward and forward manualwith a normal distribution), median [used only to de-
scribe the screening homocyst(e)ine levels for individual stepwise elimination was performed using existing clini-
cal information and by sequentially removing predictorgroups since they were not normally distributed], or pro-
portions and 95% confidence intervals where appro- variables in which the P value was .0.10.
The sample size calculation was based on our primarypriate. Differences in baseline variables between the pla-
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Table 1. Baseline characteristics
Overall (N 5 81) P value comparing placebo,
(95% CI) 5 mg and 20 mg folic acid groups
Age years 63.5 (60.1, 66.8) 0.47
Sex % male 47.6 (36.4, 58.9) 0.39
Diabetes % 26.8 (17.6, 37.8) 0.66
Years on dialysis 3.6 (2.8, 4.5) 0.46
Baseline folate intake mg/day 0.70 (0.62, 0.77) 0.46
Screening homocyst(e)ine lmol/L 27.7 (25.5, 29.8) 0.39a
Screening RBC folate nmol/L 1676 (1436, 1916) 0.43
Screening vitamin B12 pmol/L 437 (326, 548) 0.54
aKruskal-Wallis test
hypothesis. With 25 patients in each arm, our study had folic acid supplementation prior to the study experienced
the greatest decrease in homocyst(e)ine after the four80% power at a two-tailed a 5 0.05 to demonstrate a
25% difference in total homocyst(e)ine levels between weeks of treatment with Diavitee (226.0%) compared
with those who were receiving Diavitee daily (212.6%)the placebo, folic acid 5 mg, and folic acid 20 mg groups.
In addition, with 30 patients in the serine phase of the prior to the study (P 5 0.027). The decrease in homocys-
t(e)ine seen in those patients already receiving Diaviteetrial and using a paired t test, our study had 80% power
at a two-tailed a 5 0.05 to detect a 25% difference daily may reflect enhanced drug compliance during the
monitored phase of the study or regression to the mean.in total homocyst(e)ine levels before and after serine
supplementation. In phase 2, during which 1 mg of vitamin B12 was given
daily for two weeks, homocyst(e)ine levels were reduced
from 22.4 to 18.6 mmol/L (mean reduction 16.7%, 95%
RESULTS
CI, 11.8 to 21.6%, P , 0.001). During this period, vitamin
Eighty-one (94.2%) and 78 (90.7%) patients com- B12 levels increased, as expected, from 470 to 893 pmol/L
pleted phase 2 and phase 3 of the protocol, respectively. (P , 0.001). Over the first eight weeks of this study, the
Two patients were lost to transplant, and one was lost combination of daily Diavitee and vitamin B12 reduced
to death (pneumonia). Two lost interest in the study, homocyst(e)ine levels by 32.7% (95% CI, 25.6 to 39.8%)
and four developed concurrent illness felt to be unrela- compared with screening homocyst(e)ine levels.
ted to the study medications, but that prompted their In phase 3, there was no difference in mean reduction
withdrawal from the study (2 developed constipation, of homocyst(e)ine levels after therapy with 5 or 20 mg
1 developed nausea/vomiting due to diabetic gastropa- of folic acid compared with placebo (P 5 0.35; Table 3).
resis, and 1 noted an increased tendency to dialyzer clot- This suggests no advantage, in terms of homocyst(e)ine
ting). The results discussed later in this article are from lowering, to supplementation of hemodialysis patients
the 81 patients who had at least two blood samples col- with .1 mg of folic acid per day in patients already
lected, thus enabling data analysis. Baseline clinical char- receiving 1 mg of vitamin B12. When evaluating the pla-
acteristics were similar across the three treatment arms cebo and folic acid groups together, there was a trend
for all variables tested (Table 1). No patient was deficient toward a mean decrease in homocyst(e)ine of 5.9%
in RBC folate or vitamin B12 at baseline, as defined by (P 5 0.08) during phase 3, which may have been due to
normal laboratory values. ongoing treatment with vitamin B12 since vitamin B12
The etiology of renal failure was diabetes mellitus levels continued to increase during this phase from 890 to
26.8%, glomerulonephritis 28.1%, hypertension 13.4%, 1005 pmol/L (P , 0.001). After week 12 of the protocol,
interstitial nephritis (including reflux nephropathy) 8.6%, homocyst(e)ine levels had been reduced overall by
autosomal-dominant polycystic kidney disease 6.1%, other 36.1% (95% CI, 29.1 to 43.5%).
7.3%, and unknown 9.8% and was similar among the During phase 4, the additional treatment with serine
three treatment arms (P 5 0.58). Average compliance therapy for two weeks did not significantly reduce homo-
by pill count was 91.8%, and this was supported by a cyst(e)ine levels (20.62 mmol/L, 95% CI, 20.5 to 0.2
marked elevation in vitamin B12 and RBC folate levels mmol/L, P 5 0.15). Serine levels increased from 0.077
during the trial to 230 and 158% of baseline levels, re- mmol/L (95% CI, 0.059 to 0.095 mmol/L) to 0.15 mmol/L
spectively (Table 2). (95% CI, 0.093 to 0.21 mmol/L) after the two weeks of
In phase 1, screening homocyst(e)ine levels (mean 27.7 serine therapy (P , 0.01).
mmol/L) decreased by 19.2% (95% CI 12.6 to 25.9%, Using multiple logistic regression, the only variables
P , 0.001) after four weeks of treatment with daily that appeared predictive of a 50% lowering in homocys-
t(e)ine level after therapy with Diavitee and vitaminDiavitee. Patients who were not receiving Diavitee or
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Table 2. Homocyst(e)ine, RBC folate and vitamin B12 levels at weeks 0, 4, 8, 12, and 14
Percent change Percent change Week 12: Week 14:
Week 4: (week 4 Week 8: (week 8 (after 4 weeks (after 2 weeks
Week 0: (after 4 weeks compared to (after 4 weeks compared to of placebo or of serine)
Screening levels of DiaviteTM) week 0) of vitamin B12) week 4) folic acidc (N 5 24)
Homocyst(e)ine lmol/L 27.7 22.3 219.2%a 18.6 216.7%b 17.7 17.1d
(25.5, 29.8) (21.0, 23.7) (17.6, 19.6) (16.8, 18.7) (15.5, 18.7)
RBC folate nmol/L 1676 2083 24% 2286 9.7% 2600 2512
(1436, 1916) (2006, 2160) (2188, 2384) (2497, 2702) (2337, 2688)
Vitamin B12 pmol/L 437 470 7.6% 893 90% 1009 1065
(326, 548) (419, 520) (812, 973) (928, 1091) (908, 1221)
Numbers in parentheses are 95% CI.
aP , 0.001 for comparison of week 4 and week 0
bP , 0.001 for comparison of week 8 and week 4
cPlacebo, 5 mg and 20 mg folic acid groups were combined since no difference was demonstrated between the three groups in homocyst(e)ine reduction as shown
in Table 3
dP 5 0.15 for comparison of week 14 and week 12
Table 3. Homocyst(e)ine, folic acid and vitamin B12 levels during phase 3 of the trial according to treatment allocation
Week 8: Post-vitamin B12 Week 12: Post-placebo/folic acid Percent
Treatment Homocyst(e)ine RBC folate Vitamin B12 Homocyst(e)ine RBC folate Vitamin B12 reduction in
allocation lmol/L nmol/L pmol/L lmol/L nmol/L pmol/L homocyst(e)ine
Placebo 19.4 2421 804 18.4 2477 875 25.1%ab
(18.3, 20.4) (2328, 2511) (729, 879) (17.3, 19.5) (2374, 2575) (795, 955)
Folic acid 5 mg 18.1 2195 966 17.3 2565 1136 24.4%a
(17.2, 19.0) (2074, 2316) (883, 1049) (16.6, 18.0) (2459, 2669) (1069, 1203)
Folic acid 20 mg 18.5 2258 893 17.6 2743 995 24.8%a
(17.4, 19.6) (2191, 2323) (814, 972) (16.6, 18.6) (2641, 2845) (908, 1082)
Numbers in parentheses are 95% confidence interval.
aHomocyst(e)ine values in week 12 compared with week 8
bP 5 0.35 for comparison of percent reduction in homocyst(e)ine achieved with placebo, 5 mg and 20 mg of folic acid
B12 were an elevated screening homocyst(e)ine level weeks and RBC folate levels increased only minimally
[odds ratio 4.1 for every 10 mmol/L increment in screen- during the four weeks of vitamin B12 therapy (Table 2).
ing homocyst(e)ine level, P 5 0.005] and a longer length Moreover, previous work has suggested that homocys-
of time on dialysis (odds ratio 1.14 for every one year t(e)ine levels reach a new baseline after four weeks of
increment in time on dialysis, P 5 0.12). treatment with a new dose of folic acid [18].
Adverse events were rare and are noted previously in Our study demonstrates no additional benefit to folic
this article for those patients who dropped out of the trial. acid therapy above 1 mg per day in hemodialysis patients
Of the patients who completed the trial, two patients who are also receiving vitamin B12. RBC folate levels,
experienced erythematous rashes, one felt to be due to which reflect tissue folate stores, increased by only 21.5%
vitamin B12 and one systemic rash that occurred in a after four weeks of treatment with 20 mg of folic acid.
patient while receiving folic acid, 5 mg. This suggests that in hemodialysis patients, doses of folic
acid above 1 mg may not be integrated properly into cells.
This may be due to saturation of cell receptors neededDISCUSSION
for entry of folic acid or due to saturation of enzymaticPrevious articles have emphasized the role of folic acid
pathways needed in the conversion of folic acid to 5-methyl-supplementation in the treatment of hyper-homocys-
tetrahydrofolate [27, 28]. If this is indeed the case, thent(e)inemia in patients with ESRD. This is the first pro-
measurement of RBC methylfolate levels (which morespective clinical trial to demonstrate that the addition of
accurately reflect functional folate capacity) may corre-oral vitamin B12 to hemodialysis patients who are not
late more closely with homocyst(e)ine levels [29].vitamin B12 deficient by laboratory standards and who are
The results of our study need to be reviewed in lightreceiving 1 mg of folic acid lowers total homocyst(e)ine
of previous clinical trials that have studied the homocys-levels significantly. It is unlikely that the 16.7% reduction
t(e)ine-lowering ability of folic acid and vitamin B12 innoted in homocyst(e)ine levels during therapy with vita-
patients with ESRD [14, 22, 24–26, 28–33]. Three uncon-min B12 was due to concomitant folic acid therapy, since
patients had been on a constant dose of folic acid for four trolled trials have examined the use of folic acid (2.5 to
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5 mg/day) in peritoneal and hemodialysis patients on no fined by an elevation in homocyst(e)ine or MMA levels
[37]. Alternatively, ESRD patients may have a defect inprevious folic acid supplementation, demonstrating a 30
to 55% reduction in homocyst(e)ine levels with short- their ability to convert vitamin B12 (what the laboratory
measures) into its active form (hydroxylcobalamin),term therapy [24–26]. A recent uncontrolled study in-
volving 11 hemodialysis patients on no folic acid or vitamin which is needed by methionine synthase in homocys-
t(e)ine metabolism [38]. Finally, binding of vitamin B12B12 supplementation who were administered a multivita-
min containing folic acid 1 mg, vitamin B12 6 mg, and to its carrier protein transcobalamin II, which is neces-
sary for entry of vitamin B12 into tissues, may be impairedvitamin B6 10 mg (very similar to the multivitamin used
in this trial) revealed a 24% reduction in homocyst(e)ine in ESRD. Defects in transcobalamin II are associated
with normal serum vitamin B2 levels but result in physio-levels [30]. In addition, two studies [14, 32] were recently
completed, including a small randomized trial by Van logical vitamin B12 deficiency, as evidenced by elevated
homocyst(e)ine and MMA levels [38, 39]. At present,Guldener et al [14], showing that treatment of patients
with either 1 mg or 5 mg of folic acid resulted in a similar however, there is no direct evidence in support of this
theory in patients with ESRD. Further research is clearlyreduction in homocyst(e)ine levels. These results, when
considered with the current study, suggest that folic acid needed.
Although we were able to demonstrate a 36.1% reduc-therapy above 1 mg per day has no additional benefits
for homocyst(e)ine lowering in this patient population. tion in homocyst(e)ine levels using Diavitee and vitamin
B12, only 13.6% of patients were able to achieve a normalTwo trials have examined the role of vitamin B12 sup-
plementation in patients with ESRD. One small uncon- homocyst(e)ine level (,13.7 mmol/L). Since our study
was completed, Touam et al in an uncontrolled study,trolled study that enrolled 14 hemodialysis patients with
low serum vitamin B12 levels demonstrated a 35% reduc- used 50 mg of intravenous folinic acid (the active form
of folic acid) once weekly to treat hemodialysis patientstion in homocyst(e)ine after monotherapy with four
weekly intravenous 1 mg doses of vitamin B12 [26]. The with hyper-homocyst(e)inemia [28]. They were able to
only other randomized placebo-controlled study done normalize homocyst(e)ine levels in 78% of their patients
with 27 hyper-homocyst(e)inemic hemodialysis patients over 11.2 months of therapy. Unfortunately, a recent
compared a combination of vitamin B12 1 mg/day and randomized study by Bostom et al comparing oral folinic
folic acid 15 mg/day with vitamin B12, 12 mg/day, and folic acid with folic acid did not demonstrate any difference
acid, 1 mg/day [22]. After eight weeks, homocyst(e)ine in terms of homocyst(e)ine lowering in hemodialysis pa-
levels were 26% lower in patients who received the high- tients with hyper-homocyst(e)inemia [33].
dose vitamin combination. This is similar to the reduction Supplementation of patients with serine at 0.05 g/kg/
noted in our study with vitamin B12 and Diavitee therapy twice per day resulted in a minimal nonsignificant reduc-
alone, and may represent the effect of vitamin B12 rather tion in homocyst(e)ine levels. This may have been due
than the postulated effect of high dose folic acid. to the inadequate sample size in the serine phase since
We were unable to demonstrate any relationship be- enrollment was not as large as planned. These results
tween individual response to oral vitamin B12 and base- are similar to a trial done in four ESRD patients that
line serum vitamin B12 levels, suggesting that serum vita- showed no reduction in homocyst(e)ine after serine sup-
min B12 levels may not be a reliable marker of vitamin plementation [7]. It seems unlikely that we missed a
B12 status [34]. Elevated methylmalonic acid (MMA) clinically important reduction in homocyst(e)ine levels.
levels may identify more accurately those patients with
CONCLUSIONsuboptimal total body vitamin B12 stores who would have
a better response (in terms of homocyst(e)ine-lowering) This study demonstrates that the current best oral
to vitamin B12 supplements. However, as MMA is non- regimen for lowering homocyst(e)ine in patients with
specifically elevated in ESRD, this issue needs further ESRD on hemodialysis is 1 mg of folic acid and 1 mg
clarification [35]. of oral vitamin B12 daily. Supplementation with larger
It is interesting to speculate why vitamin B12 supple- doses of folic acid is not therapeutically beneficial. How-
mentation in patients who were already receiving the ever, other effective therapies need to be developed since
recommended dietary allowance of vitamin B12 and who only 13.6% of patients obtained normal homocyst(e)ine
had no laboratory evidence of vitamin B12 deficiency was levels with this treatment. Whether treatment will result
effective in lowering homocyst(e)ine. Impaired gastroin- in a reduction in cardiovascular risk for ESRD patients
testinal absorption seems unlikely since serum vitamin requires elucidation by further clinical trials.
B12 levels were elevated [36]. It may be that the standard
“normal” range reported by most laboratories is too low. ACKNOWLEDGMENTS
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